MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock and...
$57,780K
Proceeds from the royalty
purchase agreement
$20,000K
Proceeds from issuance of
series a preferred...
$12,557K
Proceeds from
at-the-market offering, net of...
$1,543K
Proceeds from exercise of
stock options
$91K
Net cash provided by
financing activities
$88,333K
Canceled cashflow
$3,638K
Net increase
(decrease) in cash and cash...
$12,429K
Canceled cashflow
$75,904K
Restricted stock units
withheld for tax
$1,552K
Deferred financing costs
$1,114K
Repayment of royalty
liability
$972K
Stock-based compensation
$11,978K
Accounts payable,
accrued expenses and...
$4,866K
Non-cash interest
expense on liability...
$2,048K
Prepaid expenses and
other assets
-$880K
Non-cash lease expense
$607K
Depreciation and
amortization
$327K
Amortization of deferred
financing fees
$215K
Sales of marketable
securities
$49,860K
Net cash used in
operating activities
-$48,963K
Net cash (used in)
provided by investing...
-$26,941K
Canceled cashflow
$20,921K
Canceled cashflow
$49,860K
Total
revenue-Partnership Revenue
$32,871K
Total
revenue-Product
$611K
Net loss
-$52,701K
Purchases of marketable
securities
$76,312K
Canceled cashflow
$33,482K
Deferred revenue
-$15,428K
Accretion and interest
related to marketable...
$811K
Operating lease
liabilities - current and...
-$550K
Change in the fair value
of derivative...
$254K
Inventory
$137K
Accounts receivable
$3K
Purchases of property and
equipment
$489K
Personnel and consulting
costs
$30,028K
Development costs-Non
Clinical Development...
$17,979K
Development costs-Clinical
Development Costs
$12,945K
Stock-based compensation
$11,978K
Other segment
expenses
$11,588K
Interest expense
(income), net
-$1,148K
Depreciation and
amortization expense
$327K
Cost of product
revenues
$190K
Back
Back
Cash Flow
source: myfinsight.com
Orchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings, Inc. (OBIO)